Reuters logo
BRIEF-Summit announces positive top-line data from an exploratory phase 2 supporting Ridinilazole
September 5, 2017 / 11:37 AM / 21 days ago

BRIEF-Summit announces positive top-line data from an exploratory phase 2 supporting Ridinilazole

Sept 5 (Reuters) - Summit Therapeutics Plc

* Summit announces positive top-line data from an exploratory phase 2 clinical trial supporting Ridinilazole as a highly selective antibiotic for the treatment of CDI

* Secondary endpoint of SCR, was achieved in 7 of 14 Ridinilazole treated patients and six of 13 fidaxomicin treated patients

* Summit Therapeutics Plc - look forward to initiating phase 3 clinical trials in first half of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below